Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
WOAAAAAAAAA Nice start here
NNBP 852K so far +20%
NNBP 852K so far +20%
NNBP news and volume >> Nanobac Pharmaceuticals and Eureka Genomics Agree to Terms for Merger
2 minutes ago - Market Wire
Related Companies
Symbol Last %Chg
NNBP 0.0031 3.33%
As of 9:47 AM ET 3/17/09
Nanobac Pharmaceuticals Inc. (PINKSHEETS: NNBP) (Nanobac) and privately held Eureka Genomics (EG) announced the signing of a Memorandum of Understanding, which delineates the terms and conditions under which Nanobac proposes to merge with Eureka in a stock and cash transaction.
The proposed merger would involve, among other things, a reverse stock split of shares in Nanobac Pharmaceuticals. When the merger is consummated, the Nanobac Pharmaceuticals name will be changed to Eureka Genomics, Inc. Subject to regulatory approvals and customary closing conditions, this transaction is currently expected to close during the second quarter of 2009.
Under the terms of the agreement, Nanobac will issue new shares of its common stock to EG stockholders who are expected to own 85 percent of the combined company on a fully diluted basis. This ratio is subject to potential adjustments as described in the Memorandum of Understanding agreement. Further, Nanobac has provided initial funding to EG and the transaction contemplates the infusion of significant capital so as to allow EG to achieve its business plan.
"We are excited about the opportunity to merge with a company that is redefining functional genomics and bioinformatics, and is well positioned to play an important role in the development of the next generation of diagnostic tests, medicines, and cleantech," said Dr. Benedict Maniscalco, Nanobac Pharmaceuticals Co-Chairman of the Board. "We believe that this merger is the right move for Nanobac and could lead to a significant increase in shareholder value."
"This merger is an important step in our R&D and business development efforts, and we, too, are confident that it will help us build significant shareholder value," said Eureka Genomics Chief Financial Officer and Chief Operating Officer Didier Perez. "Indeed, this merger will help us accelerate our efforts to advance and partner our next-generation functional genomics platform technology and bioinformatic analyses, which we have demonstrated can rapidly glean valuable and robust insights into the complex biological systems that we believe will transform the development of highly valuable, cost-effective diagnostics, therapeutics, vaccines, and cleantech products."
About Eureka Genomics
Eureka leverages a proprietary genomics platform technology to develop next-generation functional genomic insights into complex biological systems, which has the potential to help inform and accelerate the development of high-value, cost-effective diagnostics, therapeutics, vaccines, and cleantech products.
Eureka Genomics' core technology was developed at the University of Houston Bioinformatics Laboratory under the direction of Professor Yuri Romanov, a leading expert in the field of functional genomics and complex biological systems. Key backing for the development of the firm's proprietary technology came from the U.S. National Institutes of Health, the U.S. Department of Homeland Security Science and Technology Directorate, the Texas Learning and Computational Center, and the W. M. Keck Foundation.
The power of these novel algorithms and robust data structures, which provide the backbone of Eureka's bioinformatics analyses, have been validated in proof-of-concept studies with some of the world's leading biopharma firms, the U.S. government, and a number of leading U.S. academic institutions.
Safe Harbor
Investors are cautioned that certain statements in this document, some statements in periodic press releases and some oral statements of Nanobac Pharmaceuticals, Inc. officials are "Forward-Looking Statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Act"). Forward-Looking statements include statements which are predictive in nature, which depend upon or refer to future events or conditions, which include words such as "believes," "anticipates," "intends," "plans," "expects," and similar expressions. In addition, any statements concerning future financial performance (including future revenues, earnings or growth rates), ongoing business strategies or prospects, and possible future Nanobac Pharmaceuticals, Inc. actions, which may be provided by management, are also forward-looking statements as defined by the Act. Forward-Looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance or achievements of the Company to materially differ from any future results, performance or achievements expressed or implied by such forward-looking statements and to vary significantly from reporting period to reporting period. Although management believes that the assumptions will, in fact, prove to be correct or that actual future results will not be different from the expectations expressed in this report. These statements are not guarantees of future performance and Nanobac Pharmaceuticals, Inc. has no specific intention to update these statements.
Nanobac Pharmaceuticals Contact:
Alex H. Edwards, III
Director
813-637-2233
www.nanobac.com
Eureka Genomics Contact:
Didier Perez
CFO & COO
415-269-0666
Email Contact
www.eurekagenomics.com
SOURCE: Nanobac Pharmaceuticals
NNBP news >>> Nanobac Pharmaceuticals and Eureka Genomics Agree to Terms for Merger
2 minutes ago - Market Wire
Related Companies
Symbol Last %Chg
NNBP 0.0031 3.33%
As of 9:47 AM ET 3/17/09
Nanobac Pharmaceuticals Inc. (PINKSHEETS: NNBP) (Nanobac) and privately held Eureka Genomics (EG) announced the signing of a Memorandum of Understanding, which delineates the terms and conditions under which Nanobac proposes to merge with Eureka in a stock and cash transaction.
The proposed merger would involve, among other things, a reverse stock split of shares in Nanobac Pharmaceuticals. When the merger is consummated, the Nanobac Pharmaceuticals name will be changed to Eureka Genomics, Inc. Subject to regulatory approvals and customary closing conditions, this transaction is currently expected to close during the second quarter of 2009.
Under the terms of the agreement, Nanobac will issue new shares of its common stock to EG stockholders who are expected to own 85 percent of the combined company on a fully diluted basis. This ratio is subject to potential adjustments as described in the Memorandum of Understanding agreement. Further, Nanobac has provided initial funding to EG and the transaction contemplates the infusion of significant capital so as to allow EG to achieve its business plan.
"We are excited about the opportunity to merge with a company that is redefining functional genomics and bioinformatics, and is well positioned to play an important role in the development of the next generation of diagnostic tests, medicines, and cleantech," said Dr. Benedict Maniscalco, Nanobac Pharmaceuticals Co-Chairman of the Board. "We believe that this merger is the right move for Nanobac and could lead to a significant increase in shareholder value."
"This merger is an important step in our R&D and business development efforts, and we, too, are confident that it will help us build significant shareholder value," said Eureka Genomics Chief Financial Officer and Chief Operating Officer Didier Perez. "Indeed, this merger will help us accelerate our efforts to advance and partner our next-generation functional genomics platform technology and bioinformatic analyses, which we have demonstrated can rapidly glean valuable and robust insights into the complex biological systems that we believe will transform the development of highly valuable, cost-effective diagnostics, therapeutics, vaccines, and cleantech products."
About Eureka Genomics
Eureka leverages a proprietary genomics platform technology to develop next-generation functional genomic insights into complex biological systems, which has the potential to help inform and accelerate the development of high-value, cost-effective diagnostics, therapeutics, vaccines, and cleantech products.
Eureka Genomics' core technology was developed at the University of Houston Bioinformatics Laboratory under the direction of Professor Yuri Romanov, a leading expert in the field of functional genomics and complex biological systems. Key backing for the development of the firm's proprietary technology came from the U.S. National Institutes of Health, the U.S. Department of Homeland Security Science and Technology Directorate, the Texas Learning and Computational Center, and the W. M. Keck Foundation.
The power of these novel algorithms and robust data structures, which provide the backbone of Eureka's bioinformatics analyses, have been validated in proof-of-concept studies with some of the world's leading biopharma firms, the U.S. government, and a number of leading U.S. academic institutions.
Safe Harbor
Investors are cautioned that certain statements in this document, some statements in periodic press releases and some oral statements of Nanobac Pharmaceuticals, Inc. officials are "Forward-Looking Statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Act"). Forward-Looking statements include statements which are predictive in nature, which depend upon or refer to future events or conditions, which include words such as "believes," "anticipates," "intends," "plans," "expects," and similar expressions. In addition, any statements concerning future financial performance (including future revenues, earnings or growth rates), ongoing business strategies or prospects, and possible future Nanobac Pharmaceuticals, Inc. actions, which may be provided by management, are also forward-looking statements as defined by the Act. Forward-Looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance or achievements of the Company to materially differ from any future results, performance or achievements expressed or implied by such forward-looking statements and to vary significantly from reporting period to reporting period. Although management believes that the assumptions will, in fact, prove to be correct or that actual future results will not be different from the expectations expressed in this report. These statements are not guarantees of future performance and Nanobac Pharmaceuticals, Inc. has no specific intention to update these statements.
Nanobac Pharmaceuticals Contact:
Alex H. Edwards, III
Director
813-637-2233
www.nanobac.com
Eureka Genomics Contact:
Didier Perez
CFO & COO
415-269-0666
Email Contact
www.eurekagenomics.com
SOURCE: Nanobac Pharmaceuticals
AIG nice
IHGP Starting out interesting here
IHGP Starting out interesting here
IHGP SWEEEET
+57% over 8m now ROCKIN
over 3M served not even 2 hours sweeeeeeeeeeet
+42% here...hmmmm looks great
EUOK news--Euoko Skin Care to Launch at Barneys New York
32 minutes ago - Market Wire
Related Companies
Symbol Last %Chg
EUOK 0.34 6.25%
As of 9:33 AM ET 3/9/09
EUOKO, a luxury brand of Euoko Group Inc. (OTCBB: EUOK), announced today that it has partnered with Barneys New York for a launch in New York, San Francisco, Boston, Beverly Hills and Scottsdale in September 2009.
Headquartered in Toronto, Canada, Euoko is an advanced luxury skin care brand represented in more than 20 countries and territories, through such leading retail partners as Bergdorf Goodman, Neiman Marcus, Saks Fifth Avenue, Bliss, La Rinascente, 10 Corso Como, Ludwig Beck, Andrew's and Ogilvy, amongst many others.
"This positioning strengthens our rapidly-growing partnership with leading luxury retailers worldwide and reinforces our commitment to quality and innovation. We're going to do something very special at Barneys," said Brandon Truaxe, founder, President and CEO.
Questions and comments regarding this press release should be addressed to Jackie Wortman at (416) 657-3456, extension 320 or via jwortman@euoko.com. For brand information, visit www.euoko.com. For investor information about Euoko Group Inc., visit www.euokogroup.com.
All trademarks used in this release belong to their respective owners.
About Euoko Group Inc. (www.euoko.com, www.euokogroup.com):
Euoko Group Inc. develops, markets and distributes scientifically-advanced, innovative skin treatments for luxury and mass markets. The luxury brand, Euoko, is the company's flagship brand. Euoko's current portfolio targets the most demanding class of luxury skin care customers and consists of 25 treatments spanning five collections that offer comprehensive solutions to such skin concerns as wrinkles, fine lines, under-eye dark circles, dark spots, pigmentation concerns, acne, oxidation, environmental exposure and skin fatigue. Euoko's well-appointed, understated primary and secondary packaging communicates innovation, science, modernism and clean sophistication, while reflecting the prestige positioning of the portfolio. Euoko's products are represented through premium distribution channels in more than twenty countries and territories. Since the introduction of its products in September 2007, Euoko has achieved retail partnerships with such premium department stores as Bergdorf Goodman, Saks Fifth Avenue, Neiman Marcus, Printemps (France), Harrods (United Kingdom), La Rinascente (Italy), Ogilvy and Andrew's (Canada), Ludwig Beck (Germany), as well as such premier retailers as Bliss (USA), a subsidiary of Starwood Hotels and Resorts. Euoko's products are also sold globally through the company's internally-operated, multi-currency, multi-lingual website (www.euoko.com) and at 1.800.98.EUOKO (US/Canada). Euoko Group Inc. operates an investor communication website at www.euokogroup.com.
Forward-Looking Statements
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, including without limitation those statements regarding the effectiveness of our products, our ability to establish Euoko as a strong brand, to achieve distribution in retail channels or to be able to exploit, develop, acquire, finance, operate, or make profitable, any of the commercial opportunities discussed or described herein. We will not assume any obligation to update any of the forward-looking statements to reflect any events, facts, or circumstances that may arise other than as may be required by applicable law or regulation.
Contacts:
Euoko Group Inc.
Jackie Wortman
(416) 657-3456, extension 320
Email: jwortman@euoko.com
Website: www.euoko.com or www.euokogroup.com
EUOK news--Euoko Skin Care to Launch at Barneys New York
32 minutes ago - Market Wire
Related Companies
Symbol Last %Chg
EUOK 0.34 6.25%
As of 9:33 AM ET 3/9/09
EUOKO, a luxury brand of Euoko Group Inc. (OTCBB: EUOK), announced today that it has partnered with Barneys New York for a launch in New York, San Francisco, Boston, Beverly Hills and Scottsdale in September 2009.
Headquartered in Toronto, Canada, Euoko is an advanced luxury skin care brand represented in more than 20 countries and territories, through such leading retail partners as Bergdorf Goodman, Neiman Marcus, Saks Fifth Avenue, Bliss, La Rinascente, 10 Corso Como, Ludwig Beck, Andrew's and Ogilvy, amongst many others.
"This positioning strengthens our rapidly-growing partnership with leading luxury retailers worldwide and reinforces our commitment to quality and innovation. We're going to do something very special at Barneys," said Brandon Truaxe, founder, President and CEO.
Questions and comments regarding this press release should be addressed to Jackie Wortman at (416) 657-3456, extension 320 or via jwortman@euoko.com. For brand information, visit www.euoko.com. For investor information about Euoko Group Inc., visit www.euokogroup.com.
All trademarks used in this release belong to their respective owners.
About Euoko Group Inc. (www.euoko.com, www.euokogroup.com):
Euoko Group Inc. develops, markets and distributes scientifically-advanced, innovative skin treatments for luxury and mass markets. The luxury brand, Euoko, is the company's flagship brand. Euoko's current portfolio targets the most demanding class of luxury skin care customers and consists of 25 treatments spanning five collections that offer comprehensive solutions to such skin concerns as wrinkles, fine lines, under-eye dark circles, dark spots, pigmentation concerns, acne, oxidation, environmental exposure and skin fatigue. Euoko's well-appointed, understated primary and secondary packaging communicates innovation, science, modernism and clean sophistication, while reflecting the prestige positioning of the portfolio. Euoko's products are represented through premium distribution channels in more than twenty countries and territories. Since the introduction of its products in September 2007, Euoko has achieved retail partnerships with such premium department stores as Bergdorf Goodman, Saks Fifth Avenue, Neiman Marcus, Printemps (France), Harrods (United Kingdom), La Rinascente (Italy), Ogilvy and Andrew's (Canada), Ludwig Beck (Germany), as well as such premier retailers as Bliss (USA), a subsidiary of Starwood Hotels and Resorts. Euoko's products are also sold globally through the company's internally-operated, multi-currency, multi-lingual website (www.euoko.com) and at 1.800.98.EUOKO (US/Canada). Euoko Group Inc. operates an investor communication website at www.euokogroup.com.
Forward-Looking Statements
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, including without limitation those statements regarding the effectiveness of our products, our ability to establish Euoko as a strong brand, to achieve distribution in retail channels or to be able to exploit, develop, acquire, finance, operate, or make profitable, any of the commercial opportunities discussed or described herein. We will not assume any obligation to update any of the forward-looking statements to reflect any events, facts, or circumstances that may arise other than as may be required by applicable law or regulation.
Contacts:
Euoko Group Inc.
Jackie Wortman
(416) 657-3456, extension 320
Email: jwortman@euoko.com
Website: www.euoko.com or www.euokogroup.com
IHGP big volume today
EUOK ADDED .27 SURFFFS UPPPPP
EUOK heard some things----RADAR
EUOK heard some things----RADAR
SYMW NEWS---GARDNERVILLE, NV--(MARKET WIRE)--Mar 5, 2009 -- SymPowerco Corporation (Other OTC:SYMW.PK - News) CEO John Davenport today announces the company's plans to establish an Industrial Design Program that relates to the creation and development of concepts and specifications that optimize the function, value and appearance of SymPowerco's future products and systems for the benefit of both SymPowerco and its future customers.
Related Quotes
Symbol Price Change
SYMW.PK 0.0012 0.0000
{"s" : "symw.pk","k" : "c10,l10,p20,t10","o" : "","j" : ""} The program will include the development of design aesthetics and usability as they relate to marketability and production. The program is expected to create and execute design solutions with respect to form, user ergonomics, engineering, marketing, brand development and sales.
The Industrial Design Program is intended to form an integral part of the recently announced SymPowerco Commercial Design Project. The multiphase SymPowerco Commercial Design Project encompasses all facets of the design of various commercial products for the anticipated markets of the company's Flowing Electrolyte Direct Methanol Fuel Cell (FEDMFC) and Hybrid Power Systems. The project is intended to run concurrently with SymPowerco's FEDMFC development program at Carleton University's Department of Mechanical and Aerospace Engineering in Ottawa, Canada.
SymPowerco Corporation develops advanced fuel cell and power delivery systems for the rapidly growing personal transportation and portable power system markets being created by today's energy and environmental challenges.
Except for historical information contained herein, the matters set forth above may be forward-looking statements that involve certain risks and uncertainties that could cause actual results to differ from those in the forward-looking statements. Words such as "anticipate," "believe," "estimate," "expect," "intend" and similar expressions, as they relate to the Company or its management, identify forward-looking statements. Such forward-looking statements are based on the current beliefs of management, as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors such as the level of business and consumer spending, the amount of sales of the Company's products, the competitive environment within the industry, the ability of the Company to continue to expand its operations, the level of costs incurred in connection with the Company's expansion efforts, economic conditions in the industry and the financial strength of the Company's customers and suppliers. The Company does not undertake any obligation to update such forward-looking statements. Investors are also directed to consider all other risks and uncertainties.
Contact:
Contact:
Investor Relations: 775-636-8486
Email Contact: Email Contact
SYMW----GARDNERVILLE, NV--(MARKET WIRE)--Mar 5, 2009 -- SymPowerco Corporation (Other OTC:SYMW.PK - News) CEO John Davenport today announces the company's plans to establish an Industrial Design Program that relates to the creation and development of concepts and specifications that optimize the function, value and appearance of SymPowerco's future products and systems for the benefit of both SymPowerco and its future customers.
Related Quotes
Symbol Price Change
SYMW.PK 0.0012 0.0000
{"s" : "symw.pk","k" : "c10,l10,p20,t10","o" : "","j" : ""} The program will include the development of design aesthetics and usability as they relate to marketability and production. The program is expected to create and execute design solutions with respect to form, user ergonomics, engineering, marketing, brand development and sales.
The Industrial Design Program is intended to form an integral part of the recently announced SymPowerco Commercial Design Project. The multiphase SymPowerco Commercial Design Project encompasses all facets of the design of various commercial products for the anticipated markets of the company's Flowing Electrolyte Direct Methanol Fuel Cell (FEDMFC) and Hybrid Power Systems. The project is intended to run concurrently with SymPowerco's FEDMFC development program at Carleton University's Department of Mechanical and Aerospace Engineering in Ottawa, Canada.
SymPowerco Corporation develops advanced fuel cell and power delivery systems for the rapidly growing personal transportation and portable power system markets being created by today's energy and environmental challenges.
Except for historical information contained herein, the matters set forth above may be forward-looking statements that involve certain risks and uncertainties that could cause actual results to differ from those in the forward-looking statements. Words such as "anticipate," "believe," "estimate," "expect," "intend" and similar expressions, as they relate to the Company or its management, identify forward-looking statements. Such forward-looking statements are based on the current beliefs of management, as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors such as the level of business and consumer spending, the amount of sales of the Company's products, the competitive environment within the industry, the ability of the Company to continue to expand its operations, the level of costs incurred in connection with the Company's expansion efforts, economic conditions in the industry and the financial strength of the Company's customers and suppliers. The Company does not undertake any obligation to update such forward-looking statements. Investors are also directed to consider all other risks and uncertainties.
Contact:
Contact:
Investor Relations: 775-636-8486
Email Contact: Email Contact
SYMW SURFFFFS UPPPPPPPP
SYMW news and volume coming in here
IMGR nice day here for no news
IMGR nice...any news?
IMGR GETTIN JIGGY
IMGR nice recovery
so you're saying theres a chance....lol
But whats the difference? we are her to trade these POS pinkies right? We need the promo guys to make money. If they don't promo a stock it goes nowhere...lol I don't care what happens to it after I cash out bra...Buy Disney
don't remember
I made money on that too
didn't they do BANI?
Just promo shares imo--real company here
You only see negative lmao I see buying opp bra
It's called EXCITEMENT It's why we're here !!!
Whats wrong with u guyz? geeeez, this stock tripled in no time. If you didn't get in at ground floor like me and added too high thats why the pumping bothers you now? Just a bad trader bra......weeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeee
SYMW >>>>> HOLLA
IMGR SYMW sweeeet
IMGR +37% nice
IMGR +37% NOW
IMGR GXPI Quinella for today